Tools
Upgrade to Pro 🌟

Upgrade for Pro stock ideas, Al signals, and more search.

Learn More

UNCY

Unicycive Therapeutics, Inc. · NASDAQ

Performance

+5.16%

1W

+18.74%

1M

+35.88%

3M

-51.02%

6M

-41.29%

YTD

-2.04%

1Y

Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Technical Analysis of UNCY 2024-11-20

The stock exhibits a bullish sentiment overall, with a strong Moving Average Score of 76 indicating positive momentum, while the Technical Score of 65 further supports this outlook. However, the Oscillators Score of 53 suggests a more neutral stance, indicating potential caution in the short term despite the overall bullish trend.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of UNCY

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.